Gastroenterologie
a hepatologie

Therapy of portal hypertension using transjugular intrahepatic portosystemic shunt - first 1,000 procedures in UH Hradec Králové

Antonín Krajina ^{Orcid.org  1}, Petr Hůlek^2,3, Vendelín Chovanec ^{Orcid.org  1}, Ondřej Renc ^{Orcid.org  1}, Tomáš Fejfar ^{Orcid.org  2}, Václav Jirkovský ^{Orcid.org  2}, Václav Šafka ^Orcid.org  , Štěpán Šembera ^{Orcid.org  2}, Tomáš Vaňásek ^{Orcid.org  4}, Miroslav Lojík¹, Jan Raupach¹

+ Affiliation
¹ Radiologická klinika LF UK a FN Hradec Králové
² II. interní gastroenterologická klinika LF UK a FN Hradec Králové
³ Katedra interní oborů, LF OU v Ostravě
⁴ Hepato-gastroenterologie HK, s.r.o., Hradec Králové

Summary

Transjugular intrahepatic portosystemic shunt (TIPS) has been available for clinical practice since 1989, and in the Czech Republic since 1992. It is mostly used in patients suffering from liver cirrhosis and related complications such asGI bleeding or large ascites. In fact it is a side-to-side portacaval anastomosis reinforced with a metal stent and created by interventional radiologist without surgery. In the course of the 25 years of its clinical use, some changes have occurred: more than one-third of patients suffer from hepatic encephalopathy, but treatment with rifaximin is successful in most of them. The bare stent used for TIPS in the initial period, having a much higher risk of patency problems, was replaced by a covered stent (stent-graft). Though many indications were specified, some others still await confirmation, e.g. indication of TIPS according to the portacaval gradient. In the latest period, the number of indications for Gl bleeding is decreasing, but the number of procedures for ascites and hydrothorax, having more altered liver functions, is rising. TIPS reduces portal pressure but does not improve liver function, so it cannot substitute liver transplantation. TIPS is performed by an interventional radiologist, but cooperation with the hepatologist is a fundamental condition for good treatment of patients. For the time of its existence, TIPS has established a firm position in the therapeutic portfolio of portal hypertension complications.

Keywords

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users